Privium Fund Management B.V. increased its stake in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 36.5% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 23,643 shares of the company’s stock after buying an additional 6,321 shares during the period. Privium Fund Management B.V.’s holdings in Zoetis were worth $1,651,000 as of its most recent SEC filing.
Several other hedge funds have also added to or reduced their stakes in the stock. Cassaday & Co Wealth Management LLC bought a new position in shares of Zoetis during the 1st quarter valued at approximately $28,000. Wellington Grp LLC raised its holdings in shares of Zoetis by 6,675.0% in the 1st quarter. Wellington Grp LLC now owns 271 shares of the company’s stock worth $32,000 after purchasing an additional 267 shares during the period. Global Assets Advisory LLC bought a new stake in shares of Zoetis in the 1st quarter worth approximately $38,000. University of Texas Texas AM Investment Management Co. bought a new stake in shares of Zoetis in the 2nd quarter worth approximately $25,000. Finally, Dunhill Financial LLC lifted its stake in Zoetis by 519.3% in the second quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock valued at $25,000 after purchasing an additional 296 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.
Key Zoetis News
Here are the key news stories impacting Zoetis this week:
- Positive Sentiment: Adjusted EPS of $1.75 topped the $1.51 consensus, while revenue of $2.39 billion exceeded expectations of $2.30 billion. Zoetis also raised its full-year 2026 profit outlook. Zoetis Lifts Annual Outlook While Braces For Cautious Pet Economy
- Positive Sentiment: Livestock revenue grew 7% to $797 million, helping offset softness in companion-animal products. Jefferies also raised its price target to $85 from $83. Zoetis: 3 Key Takeaways for Long-Term Investors
- Negative Sentiment: Investors appear focused on ongoing pressure in the pet-health business: owners are cutting back on veterinary visits, and Zoetis is taking a cautious view of 2027. Competitive pressures and margin headwinds also weigh on the outlook. Zoetis plans cautiously for 2027 as pet owners cut back on vet visits, shares fall ZTS Q3 2026 deep dive: Competitive pressures and margin headwinds weigh on outlook
- Negative Sentiment: Despite beating estimates, quarterly revenue declined 1.3% year over year, reinforcing concerns that strength in livestock may not fully offset weaker companion-animal demand. Zoetis reports third-quarter results
Wall Street Analyst Weigh In
Several brokerages have weighed in on ZTS. TD Cowen reduced their price objective on Zoetis from $104.00 to $94.00 and set a “buy” rating for the company in a report on Tuesday, August 25th. Zacks Research upgraded Zoetis from a “strong sell” rating to a “hold” rating in a research note on Monday, October 26th. Weiss Ratings raised Zoetis from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, October 29th. Leerink Partners cut their price target on Zoetis from $95.00 to $80.00 and set a “market perform” rating for the company in a research note on Monday, July 13th. Finally, BNP Paribas Exane decreased their price objective on Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a report on Tuesday, August 11th. Eight equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $101.25.
View Our Latest Research Report on Zoetis
Zoetis Stock Performance
ZTS stock traded down $2.61 during midday trading on Friday, reaching $79.50. 6,023,502 shares of the company’s stock traded hands, compared to its average volume of 3,857,472. The firm has a market capitalization of $32.85 billion, a PE ratio of 13.52, a price-to-earnings-growth ratio of 1.23 and a beta of 0.67. The company has a 50-day moving average price of $75.68 and a two-hundred day moving average price of $92.60. Zoetis Inc. has a 52 week low of $68.77 and a 52 week high of $132.49. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08.
Zoetis (NYSE:ZTS – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported $1.75 EPS for the quarter, topping analysts’ consensus estimates of $1.51 by $0.24. The firm had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%. The business’s revenue for the quarter was down 1.3% on a year-over-year basis. During the same period last year, the company earned $1.70 earnings per share. As a group, equities analysts anticipate that Zoetis Inc. will post 6.15 EPS for the current year.
Zoetis Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be issued a dividend of $0.53 per share. The ex-dividend date of this dividend is Friday, October 30th. This represents a $2.12 dividend on an annualized basis and a yield of 2.7%. Zoetis’s dividend payout ratio is 34.93%.
About Zoetis
Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish.
The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.
Zoetis originated as Pfizer’s animal health business and became an independent public company in 2013.
Read More
- Five stocks we like better than Zoetis
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
